Pharmacist’s role in a Parkinson’s disease and movement disorders clinic

Poon, Linda H; Lee, Audrey J; Chiao, Teresa B.; Kang, Gail A.; Heath, Susan; Glass, Graham A.

doi:10.2146/ajhp110127

Cited by 14 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have reported that the participation of a pharmacist in a multidisciplinary healthcare team promotes clinical benefits for PD patients and is considered a valuable healthcare strategy [ 14 , 15 ]. Medication therapy management (MTM) is one of the pharmacist’s duties, which consists of a service undertaken by the pharmacist in conjunction with other health professionals.…”

Section: Introductionmentioning

confidence: 99%

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

et al. 2016

View full text Add to dashboard Cite

BackgroundParkinson’s disease (PD) is a neurodegenerative disease characterized by motor manifestations, autonomic and neurological disorders and sensorial symptoms. Medication therapy management (MTM) consists of a service undertaken by pharmacists to optimize pharmacological therapy results. This way, the pharmacist monitors the treatment prescribed by the doctor and formulates a healthcare plan to guarantee the treatment’s effectiveness, safety and convenience, thereby improving the patient’s quality of life (QoL).ObjectiveTo analyze the effect of MTM upon medicine-related problems, motor symptoms, autonomic disorders and QoL of patients with Parkinson’s disease, and describe the pharmaceutical interventions.MethodsQuasi-experimental uncontrolled before-and-after study carried out between September 2012 and March 2013 in a community pharmacy. Pharmacotherapy data were collected from medical prescriptions, patient diaries, medical charts and all the medicines (over-the-counter and prescription) brought by the patients to the appointment with the pharmacist. The medicine-related problems were classified as indication, effectiveness, safety and adherence. Adherence was measured through clinical interviews and the Morisky questionnaire. PD symptoms were assessed according to the patients’ and/or caregivers’ perceptions about the On/Off state of the motor symptoms and relief of the nonmotor symptoms. QoL was assessed using the PDQ-39 scores. The interventions were targeted to patients/caregivers and/or doctors, with pharmacological and non-pharmacological measures.ResultsSeventy patients were followed up, showing a decrease in medicine-related problems (1.67 ± 1.34 to 0.8 ± 0.9 (p < 0.001), positive impact on adherence (from 37 to 10 non-adherent patients, p < 0.001), QoL improvement related to emotional wellbeing (p = 0.012) and autonomic disorder. Most interventions were performed directly with the patients (73.8%), including non-pharmacological guidance (28.5%), pharmacological guidance (24.3%) and rescheduling (13.6%).ConclusionsTo carry out MTM with PD patients, the pharmacist’s expertise needs to transcend the technical knowledge about the PD pharmacological treatment. The study showed a positive effect with a decrease in the medicine-related problems after the interventions, especially improving adherence and patients’ QoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Incorporating medication therapy management follow-up visits delivered by this clinic can address various medication-related issues and will help to evaluate the utility of this clinic for PD patients. A similar integrated care model has been well-described previously in the literature 8. Poon et al8 outlined the role of the CPS for PD patients in their medical center and described how pharmacist interventions made important contributions in areas such as therapeutic problem solving and medication education, allowing providers more time for other responsibilities.…”

Section: Discussionmentioning

confidence: 94%

“…A similar integrated care model has been well-described previously in the literature 8. Poon et al8 outlined the role of the CPS for PD patients in their medical center and described how pharmacist interventions made important contributions in areas such as therapeutic problem solving and medication education, allowing providers more time for other responsibilities. Future growth of the clinic could potentially incorporate clinical video telehealth to increase access to care to patients and caregivers from the nearest VA community-based outpatient clinics.…”

Section: Discussionmentioning

confidence: 94%

Implementation and evaluation of Parkinson disease management in an outpatient clinical pharmacist–run neurology telephone clinic

Stefan

Elharar

García

2018

Mental Health Clinician

View full text Add to dashboard Cite

Parkinson disease (PD) is a progressive, debilitating neurodegenerative disease that often requires complex pharmacologic treatment regimens. Prior to this clinic, there was no involvement of a clinical pharmacy specialist (CPS) in the outpatient neurology clinic at the West Palm Beach Veterans Affairs Medical Center. This was a prospective, quality-improvement project to develop a clinical pharmacist–run neurology telephone clinic and evaluate pharmacologic and nonpharmacologic interventions in an effort to improve the quality of care for patients with PD. Additionally, the CPS conducted medication education groups to 24 patients with PD and their caregivers, if applicable, at this medical center with the purpose of promoting patient knowledge and medication awareness. Medication management was performed via telephone rather than face to face. Only patients with a concomitant mental health diagnosis for which they were receiving at least one psychotropic medication were included for individual visits due to the established scope of practice of the CPS being limited to mental health and primary care medications. Data collection included patient and clinic demographics as well as pharmacologic and nonpharmacologic interventions made for patients enrolled from January 6, 2017, through March 31, 2017. A total of 49 pharmacologic and nonpharmacologic interventions were made for 10 patients. We successfully implemented and evaluated a clinical pharmacist–run neurology telephone clinic for patients with PD. Expansion of this clinic to patients with various neurological disorders may improve access to care using an innovative method of medication management expertise by a CPS.

show abstract

“…The information collected through PAPs represents an untapped source of clinical information that can be utilized to generate information on patient characteristics, patient outcomes, treatment adherence and reimbursement practices. Several studies have investigated patient outcomes with enrollment into PAPs [2][3][4][5][6][7]. Other reports of biologic PAPs for RA have presented dosing patterns [8].…”

Section: Introductionmentioning

confidence: 99%

Etanercept Patient Assistance Program: Another Data Source for Epidemiological Studies?

Chan¹,

Seung²,

McLean³

et al. 2013

Adv Pharmacoepidemiol Drug Saf

View full text Add to dashboard Cite

show abstract

Pharmacist’s role in a Parkinson’s disease and movement disorders clinic

Cited by 14 publications

References 3 publications

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

Implementation and evaluation of Parkinson disease management in an outpatient clinical pharmacist–run neurology telephone clinic

Etanercept Patient Assistance Program: Another Data Source for Epidemiological Studies?

Contact Info

Product

Resources

About